ArticleAIDS research and human retroviruses2017
Early and Delayed Antiretroviral Therapy Results in Comparable Reductions in CD8
Abstract read
In one paragraph
Article in AIDS research and human retroviruses, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 28 citations in OpenAlex.
- Epigenetic scars of CD8Nature immunology · 2021Trial
- Targeting Ikaros and Aiolos with pomalidomide fails to reactivate or induce apoptosis of the latent HIV reservoir.Journal of virology · 2025Article
- Article
- Rapid Initiation of Antiretroviral Therapy Suppresses T Cell Pathological Proliferation and Improves Immune Recovery in People Living with HIV.Infection and drug resistance · 2025Article
- SARS-CoV-2 seropositivity in African women living with HIV and their infants.BMC infectious diseases · 2024Article
- Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study.Frontiers in pharmacology · 2024Article
- Immune checkpoint proteins are associated with persistently high liver stiffness after successful HCV treatment in people with HIV: a retrospective study.Frontiers in immunology · 2024Article
- Broadly neutralizing antibodies targeting HIV: Progress and challenges.Clinical immunology (Orlando, Fla.) · 2023Review
- Selective loss of CD107a TIGIT+ memory HIV-1-specific CD8+ T cells in PLWH over a decade of ART.eLife · 2023Article
- Host Immunity to Mycobacterium tuberculosis Infection Is Similar in Simian Immunodeficiency Virus (SIV)-Infected, Antiretroviral Therapy-Treated and SIV-Naïve Juvenile Macaques.Infection and immunity · 2023Article
- COVID-19 Outcomes and Risk Factors Among People Living with HIV.Current HIV/AIDS reports · 2022Review
- TIGIT marks exhausted T cells and serves as a target for immune restoration in patients with chronic HBV infection.American journal of translational research · 2022Article
- Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.Journal of immunology (Baltimore, Md. : 1950) · 2022Article
- Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era.Frontiers in immunology · 2022Review
- Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy.Frontiers in immunology · 2021Observational
- High CD45 expression of CD8+ and CD4+ T cells correlates with the size of HIV-1 reservoir in blood.Scientific reports · 2020Article
- Article
- Harnessing CD8Frontiers in immunology · 2019Review
- A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation.Nature communications · 2018Article
- Immune checkpoint blockade in infectious diseases.Nature reviews. Immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Rachel Lena Rutishauser1 Department of Medicine, University of California , San Francisco, San Francisco, California.
Wendy Hartogensis2 Department of Epidemiology and Biostatistics, University of California , San Francisco, San Francisco, California.
Christian Deo Deguit1 Department of Medicine, University of California , San Francisco, San Francisco, California.
Melissa Krone2 Department of Epidemiology and Biostatistics, University of California , San Francisco, San Francisco, California.
Rebecca Hoh1 Department of Medicine, University of California , San Francisco, San Francisco, California.
Frederick M Hecht1 Department of Medicine, University of California , San Francisco, San Francisco, California.
Christopher D Pilcher1 Department of Medicine, University of California , San Francisco, San Francisco, California.
Peter Bacchetti2 Department of Epidemiology and Biostatistics, University of California , San Francisco, San Francisco, California.
Steven G Deeks1 Department of Medicine, University of California , San Francisco, San Francisco, California.
Peter W Hunt1 Department of Medicine, University of California , San Francisco, San Francisco, California.
Joseph M McCune1 Department of Medicine, University of California , San Francisco, San Francisco, California.
University of California, San Francisco · USUniversity of the Philippines Manila · PH
Funding
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2MUnsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4MVirology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6MViral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT, MCCUNE, JOSEPH M · 2011 to 2015
$29.5MTraining in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4MDeterminants of Functional Immune Defects in Treated HIV Infection and AgingR01AI110271 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HUNT, PETER W · 2014 to 2018
$3.9MHost Factors Influencing HIV Viral Load and Infectivity in SemenR01HD074511 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PILCHER, CHRISTOPHER D · 2012 to 2016
$3.1MPreventing the Establishment of Enfuvirtide-resistance in the Latent ReservoirK24AI069994 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT · 2007 to 2016
$1.5MNCRR NIH HHS UL1 RR024131NIAID NIH HHS K24 AI069994NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI110271NIAID NIH HHS R24 AI067039NIAID NIH HHS T32 AI060530NIAID NIH HHS U19 AI096109NICHD NIH HHS R01 HD074511
Abstract
In untreated HIV infection, CD8
Indexed as
ImmunophenotypingSecondary PreventionAdultAnti-Retroviral AgentsCD8-Positive T-LymphocytesCohort StudiesFemaleHIV InfectionsHumansMaleMiddle AgedYoung AdultAnti-Retroviral AgentsCD8+ T cellEarly ARTexhaustionHIV
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.